logo
Plus   Neg
Share
Email

Sanofi: FDA To Review Isatuximab As Potential Treatment For RRMM

French pharma major Sanofi (SNYNF,SNY) announced Wednesday that the U.S. Food and Drug Administration has accepted for review the Biologics License Application or BLA for isatuximab to treat patients with relapsed/refractory multiple myeloma or RRMM.

The target action date for the FDA decision is April 30, 2020. Isatuximab is an investigational monoclonal antibody that targets a specific epitope on the CD38 receptor of a plasma cell.

Sanofi said the BLA is based on positive results from ICARIA-MM, an open-label pivotal Phase 3 clinical trial of isatuximab in patients with RRMM.

Isatuximab received orphan designation from both the FDA and the European Medicines Agency for relapsed/refractory multiple myeloma. In the second quarter of 2019, the EMA accepted for review the Marketing Authorization Application.

The company noted that Isatuximab is currently being evaluated in multiple ongoing Phase 3 clinical trials in combination with current standard treatments for people with relapsed/refractory or newly-diagnosed multiple myeloma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT